EC approves Mayzent® for secondary progressive multiple sclerosis
Mayzent (siponimod) has been approved by the European Commission (EC)…
Mayzent (siponimod) has been approved by the European Commission (EC) for adults with secondary progressive multiple sclerosis (SPMS) based on the results of the EXPAND trial.